In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
Quince Therapeutics Inc (NASDAQ: QNCX) closed the day trading at $3.57 up 2.59% from the previous closing price of $3.48. In other words, the price has increased by $2.59 from its previous closing price. On the day, 0.7 million shares were traded. QNCX stock price reached its highest trading level at $3.665 during the session, while it also had its lowest trading level at $3.4385.
Ratios:
For a better understanding of QNCX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.12 and its Current Ratio is at 1.12. In the meantime, Its Debt-to-Equity ratio is 16.97 whereas as Long-Term Debt/Eq ratio is at 0.34.
Upgrades & Downgrades
In the most recent recommendation for this company, Citizens JMP on August 05, 2025, initiated with a Mkt Outperform rating and assigned the stock a target price of $9. On March 24, 2025, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $10.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, QNCX now has a Market Capitalization of 198782912 and an Enterprise Value of 190487920.
Stock Price History:
The Beta on a monthly basis for QNCX is 1.15, which has changed by 1.028409 over the last 52 weeks, in comparison to a change of 0.14402747 over the same period for the S&P500. Over the past 52 weeks, QNCX has reached a high of $4.55, while it has fallen to a 52-week low of $0.72. The 50-Day Moving Average of the stock is 44.10%, while the 200-Day Moving Average is calculated to be 111.48%.
Shares Statistics:
Over the past 3-months, QNCX traded about 658.96K shares per day on average, while over the past 10 days, QNCX traded about 879910 shares per day. A total of 54.49M shares are outstanding, with a floating share count of 48.30M. Insiders hold about 13.25% of the company’s shares, while institutions hold 20.78% stake in the company. Shares short for QNCX as of 1764288000 were 1551992 with a Short Ratio of 2.36, compared to 1761868800 on 1311476. Therefore, it implies a Short% of Shares Outstanding of 1551992 and a Short% of Float of 3.11.
Earnings Estimates
The dynamic stock of Quince Therapeutics Inc (QNCX) is currently being evaluated by a team of 3.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.2, with high estimates of -$0.15 and low estimates of -$0.23.
Analysts are recommending an EPS of between -$1.03 and -$1.15 for the fiscal current year, implying an average EPS of -$1.08. EPS for the following year is -$0.72, with 4.0 analysts recommending between -$0.11 and -$1.24.
